Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)
نویسندگان
چکیده
منابع مشابه
Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)
Tumour lysis syndrome (TLS) is a rare side effect of chemotherapy for solid tumours. It describes the metabolic derangements following rapid and extensive tumour cell death following a good response to chemotherapy. Symptoms are those of metabolic derangement and renal failure. Treatment involves rehydration and correction of metabolic abnormalities. TLS should be considered in high risk groups...
متن کاملHerpes zoster complicating imatinib mesylate for gastrointestinal stromal tumour.
Varicella zoster virus (VZV) infection is uncommon in patients with gastrointestinal stromal tumour (GIST) and who have not been exposed to extensive radiotherapy and/or high-dose chemotherapy. We report a 56-year-old Nigerian man with GIST who developed VZV infection while on imatinib mesylate therapy. From August 2003 to November 2005, 64 patients (GIST/CML = 6/58) were enrolled into an ongoi...
متن کاملTumour lysis syndrome in a patient with metastatic melanoma treated with biochemotherapy.
Sir, Tumour lysis syndrome (TLS) may complicate the treatment of highly proliferative, chemosensitive haematological malignancies w1x. Rapid cell death is associated with hyperuricaemia, hypocalcaemia, hyperphosphataemia, and hyperkalaemia w2x. Acute hyperuricaemic nephropathy (AHN) arises from precipitation of uric acid crystals within renal tubules and subsequent uptake into tubular epithelia...
متن کاملDevelopment and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.
PURPOSE Metastatic gastrointestinal stromal tumour (GIST) is generally an incurable disease with variable response to imatinib. We aimed to develop prognostic nomograms to predict overall survival (OS) and progression-free survival (PFS) for patients treated with imatinib. METHODS Nomograms were developed in a training cohort (n=330) of patients treated in a randomised trial (EORTC-ISG-AGITG ...
متن کاملSevere skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate.
Imatinib mesylate is a selective protein kinase inhibitor, highly active in patients with chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). Cutaneous toxicity, a well-recognized, dose-related side-effect of imatinib mesylate, has been reported in 18 to 69% of patients with GIST treated with doses ranging from 400 to 800 mg once a day. In this case-report a severe skin ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Sarcoma
سال: 2007
ISSN: 1357-714X,1369-1643
DOI: 10.1155/2007/82012